Indeed, our TIL-rich DCIS group, showing higher B-cell counts than the TIL-poor DCIS category, contained more HER2+ cases, so that is likely the strongest explanation of a relative excess of B-cells in the TIL-rich subgroup. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.